Moxifloxacin N-sulfate | Metabolite

MedKoo Cat#: 574282 | Name: Moxifloxacin N-sulfate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moxifloxacin N-sulfate is a metabolite of Moxifloxacin --- a fluoroquinolone antibiotic. Formulations containing moxifloxacin have been used in the treatment of bacterial infections such as sinusitis, chronic bronchitis, and pneumonia.

Chemical Structure

Moxifloxacin N-sulfate

CAS#234080-64-9

Theoretical Analysis

MedKoo Cat#: 574282

Name: Moxifloxacin N-sulfate

CAS#: 234080-64-9

Chemical Formula: C21H22FN3Na2O7S

Exact Mass: 525.0958

Molecular Weight: 525.46

Elemental Analysis: C, 48.00; H, 4.22; F, 3.62; N, 8.00; Na, 8.75; O, 21.31; S, 6.10

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 550.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Moxifloxacin N-sulfate

IUPAC/Chemical Name

1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1-sulfo-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, disodium salt

InChi Key

IHLPBNXQXQAMMO-WJMOHVQJSA-L

InChi Code

InChI=1S/C21H24FN3O7S.2Na/c1-32-20-17-13(19(26)14(21(27)28)9-24(17)12-4-5-12)7-15(22)18(20)23-8-11-3-2-6-25(16(11)10-23)33(29,30)31;;/h7,9,11-12,16H,2-6,8,10H2,1H3,(H,27,28)(H,29,30,31);;/q;2*+1/p-2/t11-,16+;;/m0../s1

SMILES Code

O=C1C(C([O-])=O)=CN(C2CC2)C3=C1C=C(F)C(N4C[C@@]5([H])[C@@](N(S([O-])(=O)=O)CCC5)([H])C4)=C3OC.[Na+].[Na+]

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Moxifloxacin N-sulfate is a metabolite of Moxifloxacin --- a fluoroquinolone antibiotic.

In vitro activity:

The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 μg/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. BAY 12-8039 was fourfold more active than clarithromycin but two- to fourfold less active than sparfloxacin. Furthermore, the activity of BAY 12-8039 was compared with that of sparfloxacin against the eight multistep fluoroquinolone-resistant mutants of the reference strain M. hominis PG21. A comparable increased resistance to both antibiotics was found (MIC of BAY 12-8039, 1 to 8 μg/ml; MIC of sparfloxacin, 0.06 to 4 μg/ml). BAY 12-8039 was very active against all the ureaplasma strains studied. Doxycycline-resistant strains were as susceptible as doxycycline-susceptible strains to BAY 12-8039. For all mycoplasma species (Table1), the MBCs of BAY 12-8039 were two- to eightfold higher than the MICs. These data suggest that BAY 12-8039 may be useful for the treatment of respiratory or genital infections in which mycoplasmas are involved. Reference: Antimicrob Agents Chemother. 1998 Mar; 42(3): 703–704. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105523/

In vivo activity:

Moxifloxacin treatment resulted in an increased clearance of P. aeruginosa and S. pneumoniae in the lungs of mice infected with viable bacteria indicating a bactericidal activity of moxifloxacin in our pneumonia model against both bacterial species. No viable bacteria were detected in BAL fluids of moxifloxacin-treated mice infected with 5 × 106 CFU of S. pneumoniae 24 hours post infection, whereas 7 × 103 (±3 × 103) CFU of viable S. pneumoniae were determined in BAL fluids of saline-treated control mice. In mice infected with 107 CFU of P. aeruginosa for 6 hours, 4 × 105 (±2 × 105) CFU were detected in BAL fluids of saline-treated control mice and 9 × 102 (±1.3 × 103) CFU in BAL fluids of moxifloxacin-treated mice. Interestingly, treatment with moxifloxacin affected the levels of total immune cells and neutrophils in the lungs of mice infected with viable and heat-inactivated bacteria. Treatment with moxifloxacin, as compared to saline, resulted in significantly reduced levels of total immune cells (Figure 1A to C) and neutrophils (Figure 2A to C) in BAL fluids of mice infected with a low dose or a high dose of heat-inactivated P. aeruginosa or with viable S. pneumoniae (Figures 1E and2E). There was no difference in the numbers of total immune cells in BAL fluids between moxifloxacin- and saline-treated mice infected with viable P. aeruginosa (Figures 1D and 2D). Levels of macrophages and lymphocytes in BAL fluids were not affected by treatment with moxifloxacin (data not shown). In conclusion, it is shown that moxifloxacin reduces the “hyper-inflammation” during murine pneumonia. Pretreatment with moxifloxacin attenuates local and systemic inflammation during bacterial pneumonia in mice. Reference: Respir Res. 2014; 15(1): 82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118268/

Preparing Stock Solutions

The following data is based on the product molecular weight 525.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1.Bébéar CM, Renaudin H, Boudjadja A, Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703. PMID: 9517957; PMCID: PMC105523. 2. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24. doi: 10.1128/AAC.41.8.1818. PMID: 9257770; PMCID: PMC164014. 3. Ukpo GE, Ebuehi OA, Kareem AA. Evaluation of Moxifloxacin-induced Biochemical Changes in Mice. Indian J Pharm Sci. 2012 Sep;74(5):454-7. doi: 10.4103/0250-474X.108422. PMID: 23716875; PMCID: PMC3660873. 4. Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res. 2014 Jul 17;15(1):82. doi: 10.1186/1465-9921-15-82. PMID: 25034539; PMCID: PMC4118268.

In vitro protocol:

In vivo protocol:

1. Ukpo GE, Ebuehi OA, Kareem AA. Evaluation of Moxifloxacin-induced Biochemical Changes in Mice. Indian J Pharm Sci. 2012 Sep;74(5):454-7. doi: 10.4103/0250-474X.108422. PMID: 23716875; PMCID: PMC3660873. 2. Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res. 2014 Jul 17;15(1):82. doi: 10.1186/1465-9921-15-82. PMID: 25034539; PMCID: PMC4118268.

1. Li, J., Yuan, Y., Fan, R., et al. A simple LC/MS/MS method for the determination of moxifloxacin N-sulfate in rat plasma and its application in a pharmacokinetic study. J. AOAC Int. 98(4), 921-926 (2015).